Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: A quantitative proteomic study

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4441-4470

  Niu, Ning Kui ^a,b,c   Yin, Juan Juan ^c   Yang, Yin Xue ^b   Wang, Zi Li ^a   Zhou, Zhi Wei ^c   He, Zhi Xu ^d   Chen, Xiao Wu ^e   Zhang, Xueji ^f   Duan, Wei ^g   Yang, Tianxin ^h   Zhou, Shu Feng ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d GUIZHOU MEDICAL UNIVERSITY   (China)

^e SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^g DEAKIN UNIVERSITY   (Australia)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Autophagy; Cell cycle; Cytokine; Interleukin; Liposome; NF B; Proteomics; SILAC; Tuberculosis

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2; INTERLEUKIN 6; INTERLEUKIN 8; ISONIAZID; MACROGOL; NANOPARTICLE; PYRAZINAMIDE; RIFAMPICIN; SMALL INTERFERING RNA; STREPTOMYCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; LIPOSOME; MACROGOL DERIVATIVE; TUBERCULOSTATIC AGENT;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE; CELL JUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; GENE SILENCING; GLYCOSYLATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; ISOTOPE LABELING; LIPOSOMAL DELIVERY; MACROPHAGE; MYCOBACTERIOSIS; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEOMICS; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; CELL CULTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; APOPTOSIS; AUTOPHAGY; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; LIPOSOMES; MACROPHAGES; POLYETHYLENE GLYCOLS; PROTEOMICS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUBERCULOSIS;

EID: 84939839221     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79369     Document Type: Article

References (96)

1. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–1070.
2. Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–338.
3. Tanne JH. Some progress and some missed targets in the TB epidemic. BMJ. 2014;348:g2626.
4. Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2014;5(2):a017798.
5. World Health Organization. Global Tuberculosis Report 2014. Report No 9241564652. Geneva, Switzerland: World Health Organization; 2015.
6. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don’t know can, and does, hurt us. Science. 2010;328(5980):852–856.
7. Alami NN, Yuen CM, Miramontes R, et al. Trends in tuberculosis − United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(11):229–233.
8. Turner RD, Bothamley GH. Cough and the Transmission of Tuberculosis. J Infect Dis. 2015;211(9):1367–1372.
9. Kulchavenya E. Extrapulmonary tuberculosis: are statistical reports accurate? Ther Adv Infect Dis. 2014;2(2):61–70.
10. Chaudhary P. Hepatobiliary tuberculosis. Ann Gastroenterol. 2014;27(3):207–211.
11. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva, Switzerland: World Health Organization; 2010.
12. Chan JG, Bai X, Traini D. An update on the use of rifapentine for tuberculosis therapy. Expert Opin Drug Deliv. 2014;11(3):421–431.
13. Field SK, Fisher D, Jarand JM, Cowie RL. New treatment options for multidrug-resistant tuberculosis. Ther Adv Respir Dis. 2012;6(5):255–268.
14. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet. 2004;364(9432):417–422.
15. Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057–2064.
16. Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ. 2015;350:h882.
17. Gunther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med. 2014;14(3):279–285.
18. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383(9928):1572–1579.
19. Goldstein BP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 2014;67(9):625–630.
20. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis, 2011 Update. Geneva, Switzerland: World Health Organization; 2011.
21. Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6:111–118.
22. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb). 2014;94(4):357–362.
23. Cox E, Laessig K. FDA approval of bedaquiline − the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med. 2014;371(8):689–691.
24. Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol. 2013;21(9):493–501.
25. Ryan NJ, Lo JH. Delamanid: first global approval. Drugs. 2014;74(9):1041–1045.
26. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert Opin Pharmacother. 2015;16(2):253–261.
27. Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91–100.
28. Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015;9:677–682.
29. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477.
30. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5(2):231–249.
31. Hosford JD, von Fricken ME, Lauzardo M, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2014;95(2):112–122.
32. Choudhary S, Kusum Devi V. Potential of nanotechnology as a delivery platform against tuberculosis: current research review. J Control Release. 2015;202C:65–75.
33. Griffiths G, Nystrom B, Sable SB, Khuller GK. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol. 2010;8(11):827–834.
34. Banyal S, Malik P, Tuli HS, Mukherjee TK. Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr Opin Pulm Med. 2013;19(3):289–297.
35. Dube A, Lemmer Y, Hayeshi R, et al. State of the art and future directions in nanomedicine for tuberculosis. Expert Opin Drug Deliv. 2013;10(12):1725–1734.
36. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49–88.
37. Mehanna MM, Mohyeldin SM, Elgindy NA. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J Control Release. 2014;187:183–197.
38. Kaur IP, Singh H. Nanostructured drug delivery for better management of tuberculosis. J Control Release. 2014;184:36–50.
39. Vyas SP, Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin Drug Deliv. 2007;4(2):95–99.
40. Pinheiro M, Lucio M, Lima JL, Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine (Lond). 2011;6(8):1413–1428.
41. Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm. 2015;478(2):517–529.
42. Berrington WR, Hawn TR. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol Rev. 2007;219:167–186.
43. Zuniga J, Torres-Garcia D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EJ. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol. 2012;2012:193923.
44. Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Adv Exp Med Biol. 2013;783:121–140.
45. Matucci A, Maggi E, Vultaggio A. Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents. J Rheumatol Suppl. 2014;91:17–23.
46. de Martino M, Galli L, Chiappini E. Reflections on the immunology of tuberculosis: will we ever unravel the skein? BMC Infect Dis. 2014;14(Suppl 1):S1.
47. Parandhaman DK, Narayanan S. Cell death paradigms in the pathogenesis of Mycobacterium tuberculosis infection. Front Cell Infect Microbiol. 2014;4:31.
48. Chan J, Mehta S, Bharrhan S, et al. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol. 2014;26(6):588–600.
49. Urdahl KB. Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis. Semin Immunol. 2014;26(6):578–587.
50. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27:393–422.
51. Rajaram MV, Ni B, Dodd CE, Schlesinger LS. Macrophage immunoregulatory pathways in tuberculosis. Semin Immunol. 2014;26(6):471–485.
52. Bruns H, Stenger S. New insights into the interaction of Mycobacterium tuberculosis and human macrophages. Future Microbiol. 2014;9(3):327–341.
53. Etna MP, Giacomini E, Severa M, Coccia EM. Pro- and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin Immunol. 2014;26(6):543–551.
54. Monin L, Khader SA. Chemokines in tuberculosis: the good, the bad and the ugly. Semin Immunol. 2014;26(6):552–558.
55. Dorhoi A, Kaufmann SH. Tumor necrosis factor-α in mycobacterial infection. Semin Immunol. 2014;26(3):203–209.
56. Toossi Z, Ellner JJ. The role of TGFβ in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol. 1998;87(2):107–114.
57. Friedland JS. Targeting the inflammatory response in tuberculosis. N Engl J Med. 2014;371(14):1354–1356.
58. Wu M, Aung H, Hirsch CS, Toossi Z. Inhibition of Mycobacterium tuberculosis-induced signalling by transforming growth factor-β in human mononuclear phagocytes. Scand J Immunol. 2012;75(3):301–304.
59. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511(7507):99–103.
60. Jin W, Wang Q, Wang Z, Geng G. Complete debridement for treatment of thoracolumbar spinal tuberculosis: a clinical curative effect observation. Spine J. 2014;14(6):964–970.
61. Wang Z, Shi J, Geng G, Qiu H. Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation. Eur Spine J. 2013;22(2):274–281.
62. Wang Z, Ge Z, Jin W, et al. Treatment of spinal tuberculosis with ultrashort-course chemotherapy in conjunction with partial excision of pathologic vertebrae. Spine J. 2007;7(6):671–681.
63. Qin Y, Zhou ZW, Pan ST, et al. Graphene quantum dots induce apoptosis, autophagy, and inflammatory response via p38 mitogen-activated protein kinase and nuclear factor-kappaB mediated signaling pathways in activated THP-1 macrophages. Toxicology. 2015;327:62–76.
64. Yin JJ, Sharma S, Shumyak SP, et al. Synthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatment. PLoS One. 2013;8(5):e62289.
65. Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344(2):239–259.
66. Ding YH, Zhou ZW, Ha CF, et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 2015;9:425–464.
67. Yuan CX, Zhou ZW, Yang YX, et al. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015;9:487–508.
68. Zhou ZW, Li XX, He ZX, et al. Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Devel Ther. 2015;9:1511–1554.
69. Qiu JX, Zhou ZW, He ZX, et al. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther. 2015;9:349–417.
70. Pan ST, Zhou ZW, He ZX, et al. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug Des Devel Ther. 2015;9:937–968.
71. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9–10):342–359.
72. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–549.
73. Baker SJ. PTEN enters the nuclear age. Cell. 2007;128(1):25–28.
74. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–580.
75. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157(1):65–75.
76. Hurley JH, Schulman BA. Atomistic autophagy: the structures of cellular self-digestion. Cell. 2014;157(2):300–311.
77. Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res. 2014;74(2):412–419.
78. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008;40(12):2707–2719.
79. Garcia-Monco JC. Tuberculosis. Handb Clin Neurol. 2014;121:1485–1499.
80. Horsburgh CR Jr. Tuberculosis. Eur Respir Rev. 2014;23(131):36–39.
81. Alliance T. Streptomycin. Tuberculosis (Edinb). 2008;88(2):162–163.
82. Chaisson RE, Churchyard GJ. Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis. 2010;201(5):653–655.
83. Salem II, Flasher DL, Duzgunes N. Liposome-encapsulated antibiotics. Methods Enzymol. 2005;391:261–291.
84. Sarkar S, Suresh MR. An overview of tuberculosis chemotherapy – a literature review. J Pharm Pharm Sci. 2011;14(2):148–161.
85. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–1037.
86. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 2008;10(9):995–1004.
87. Helmuth L. Microbiology – a weak link in TB bacterium is found. Science. 2000;289(5482):1123–1125.
88. Orme IM, Basaraba RJ. The formation of the granuloma in tuberculosis infection. Semin Immunol. 2014;26(6):601–609.
89. Ellner JJ. Immunoregulation in TB: observations and implications. Clin Transl Sci. 2010;3(1):23–28.
90. Li H, Liang CZ, Tao YQ, Shen CC, Chen QX. Elevated local TGF-β1 level predisposes a closed bone fracture to tuberculosis infection. Med Hypotheses. 2012;79(3):400–402.
91. Cambier CJ, Falkow S, Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell. 2014;159(7):1497–1509.
92. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–655.
93. Lima WF, Prakash TP, Murray HM, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150(5):883–894.
94. Hwang M, Kim H-J, Noh H-J, et al. TGF-β1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol. 2006;81(1):48–54.
95. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952–958.
96. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. 2006;1(6):2650–2660.